While investors making bets on R&D need the potential of big financial returns, we believe that value-based drug pricing sends the right signal to the drug industry and venture capital firms about the kind of innovation we all want funded.
Neurologist Dr. Jason Crowell sits down with ICER’s President Dr. Steve Pearson to pry open the black box of US drug pricing and to wrestle with each of the financial and ethical tensions that undergird our current medical infrastructure.
This perspective, written by David Whitrap, was first shared in our Weekly View e-newsletter, which summarizes the week’s most significant drug pricing news. To subscribe, click here. Undoubtedly, the week’s biggest news was the FDA’s approval of Biogen’s Aduhelm for the treatment of Alzheimer’s disease. ICER has already issued a statement sharing our reaction, but here’s a […]